Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.4K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.4K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.5K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.5K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.6K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.6K
Hematopoiesis01:21

Hematopoiesis

7.6K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
7.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

625
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
625

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atomically Precise Polyanionic Boron Cluster Agents with Broad-Spectrum Antiviral Activity.

Precision chemistry·2026
Same author

Lentivirus-based HPSC therapy provides effective and long-term treatment in hypophosphatasia mouse model.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

An <i>ex vivo</i> gut mucosal explant assay to compare HIV tissue susceptibility shows increased HIV susceptibility with methamphetamine exposure.

bioRxiv : the preprint server for biology·2026
Same author

Leveraging HIV-Specific CAR T Cells and Rapamycin Treatment in "Kick-and-Kill" HIV Cure Approaches.

bioRxiv : the preprint server for biology·2026
Same author

NK Cells Engineered with a Chimeric Antigen Receptor Delay HIV Rebound and Reshape HIV Reservoir Composition.

bioRxiv : the preprint server for biology·2026
Same author

CRISPR/Cas strategies to enhance CAR T-cell function and persistence via metabolic reprogramming.

Trends in biotechnology·2026

Related Experiment Video

Updated: Nov 10, 2025

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

6.8K

Robust CAR-T memory formation and function via hematopoietic stem cell delivery.

Anjie Zhen1,2, Mayra A Carrillo1,2, Wenli Mu1,2

  • 1Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America.

Plos Pathogens
|April 1, 2021
PubMed
Summary
This summary is machine-generated.

This study developed a superior Chimeric Antigen Receptor (CAR) T-cell therapy for HIV-1, enhancing immune response and viral suppression. The new D1D2CAR-41BB therapy shows improved persistence and reduced off-target effects for potential HIV-1 cure.

More Related Videos

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.5K

Related Experiment Videos

Last Updated: Nov 10, 2025

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

6.8K
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

4.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.5K

Area of Science:

  • Immunotherapy
  • Virology
  • Hematopoietic Stem Cell Transplantation

Background:

  • Current combination antiretroviral therapy (ART) cannot eradicate HIV-1 due to persistent viral reservoirs.
  • Chimeric Antigen Receptor (CAR) T-cell therapy offers a promising immunotherapy approach for HIV-1, but challenges remain in T-cell persistence and function.
  • Previous work demonstrated successful in vivo production of anti-HIV CAR T-cells from modified hematopoietic stem cells (HSCs).

Purpose of the Study:

  • To develop and evaluate second-generation CD4-based CARs (CD4CAR) for HIV-1 treatment using an HSCs-based approach.
  • To assess the efficacy of a modified truncated CD4-based CAR (D1D2CAR) and the impact of different stimulatory domains (4-1BB vs. CD28).
  • To determine if the D1D2CAR-41BB construct improves CAR T-cell differentiation, anti-viral function, and persistence in vivo.

Main Methods:

  • Development and in vivo testing of second-generation CD4-based CARs (CD4CAR) in an HSCs-based model.
  • Comparison of a modified truncated CD4-based CAR (D1D2CAR) against full-length CD4CAR for T-cell differentiation and cytotoxic T-lymphocyte (CTL) activity.
  • Evaluation of CAR T-cell function, viral suppression, and persistence in mice, with and without ART, incorporating 4-1BB or CD28 stimulatory domains.

Main Results:

  • The modified D1D2CAR demonstrated better CAR T-cell differentiation from HSCs with maintained CTL activity compared to full-length CD4CAR.
  • D1D2CAR showed no HIV infection or IL-16 stimulation, indicating reduced off-target effects.
  • Incorporation of the 4-1BB stimulatory domain, but not CD28, improved hematopoietic differentiation and anti-viral function. D1D2CAR-41BB significantly enhanced viral suppression and CAR T-cell persistence, especially in combination with ART.

Conclusions:

  • The D1D2CAR-41BB construct represents a superior CAR therapy candidate for HIV-1, outperforming the original CD4CAR.
  • This enhanced CAR exhibits improved HSC differentiation, potent viral suppression, and better T-cell persistence with reduced deleterious functions.
  • The D1D2CAR-41BB therapy warrants further clinical investigation as a potential strategy for HIV-1 cure or sustained remission.